{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:58:31Z","timestamp":1790017111850,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41429-021-00498-z","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:03:26Z","timestamp":1641384206000},"page":"136-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo"],"prefix":"10.1038","volume":"75","author":[{"given":"Kiyoko","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0720-3906","authenticated-orcid":false,"given":"Hiroyuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"498_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev.me.38.020187.002221","volume":"38","author":"DC Morrison","year":"1987","unstructured":"Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417\u201332.","journal-title":"Annu Rev Med"},{"key":"498_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.it.2012.09.004","volume":"34","author":"M Bosmann","year":"2013","unstructured":"Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013;34:129\u201336.","journal-title":"Trends Immunol"},{"key":"498_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","volume":"167","author":"JA Kellum","year":"2007","unstructured":"Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655\u201363.","journal-title":"Arch Intern Med"},{"key":"498_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cyto.2004.10.010","volume":"29","author":"S Oda","year":"2005","unstructured":"Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)\/sepsis. Cytokine 2005;29:169\u201375.","journal-title":"Cytokine"},{"key":"498_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1128\/AAC.42.5.1015","volume":"42","author":"T Kirikae","year":"1998","unstructured":"Kirikae T, Kirikae F, Saito S, Tominaga K, Tamura H, Uemura Y, et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli. Antimicrob Agents Chemother. 1998;42:1015\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"498_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1128\/AAC.00670-10","volume":"55","author":"JJ Hilliard","year":"2011","unstructured":"Hilliard JJ, Melton JL, Hall L, Abbanat D, Fernandez J, Ward CK, et al. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model. Antimicrob Agents Chemother. 2011;55:836\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"498_CR7","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/CCM.0b013e31821e87ab","volume":"39","author":"MA Puskarich","year":"2011","unstructured":"Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med. 2011;39:2066\u201371.","journal-title":"Crit Care Med"},{"key":"498_CR8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/infdis\/167.6.1336","volume":"167","author":"ME Evans","year":"1993","unstructured":"Evans ME, Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis. 1993;167:1336\u201343.","journal-title":"J Infect Dis"},{"key":"498_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bbamem.2016.01.011","volume":"1858","author":"K Brandenburg","year":"2016","unstructured":"Brandenburg K, Heinbochel L, Correa W, Lohner K. Peptides with dual mode of action: Killing bacteria and preventing endotoxin-induced sepsis. Biochim Biophys Acta. 2016;1858:971\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"498_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jac\/dkm190","volume":"60","author":"G Goscinski","year":"2007","unstructured":"Goscinski G, Tano E, L\u00f6wdin E, Sj\u00f6lin J. Propensity to release endotoxin after two repeated doses of cefuroxime in an in vitro kinetic model: higher release after the second dose. J Antimicrob Chemother. 2007;60:328\u201333.","journal-title":"J Antimicrob Chemother"},{"key":"498_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/infdis\/165.6.1033","volume":"165","author":"JJ Jackson","year":"1992","unstructured":"Jackson JJ, Kropp H. beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis. 1992;165:1033\u201341.","journal-title":"J Infect Dis"},{"key":"498_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1128\/CMR.15.1.95-110.2002","volume":"15","author":"R Nau","year":"2002","unstructured":"Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev. 2002;15:95\u2013110.","journal-title":"Clin Microbiol Rev"},{"key":"498_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00134-002-1330-6","volume":"28","author":"PM Lepper","year":"2002","unstructured":"Lepper PM, Held TK, Schneider EM, B\u00f6lke E, Gerlach H, Trautmann M. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 2002;28:824\u201333.","journal-title":"Intensive Care Med"},{"key":"498_CR14","unstructured":"Fujiwara M, Nakagawa S, Eto M, Mizunaga S Inhibition of LpxC Activity and Elimination of Lipopolysaccharide (LPS) Release by T-1228 (RC-01). [Abstract] American Society for Microbiology Microbe 2019, abstr AAR-741."},{"key":"498_CR15","doi-asserted-by":"publisher","first-page":"e00312","DOI":"10.1128\/mBio.00312-12","volume":"3","author":"L Lin","year":"2012","unstructured":"Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 2012;3:e00312\u201312.","journal-title":"MBio"},{"key":"498_CR16","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3389\/fimmu.2017.01368","volume":"8","author":"E Uribe-Querol","year":"2017","unstructured":"Uribe-Querol E, Rosales C. Control of Phagocytosis by Microbial Pathogens. Front Immunol. 2017;8:1368.","journal-title":"Front Immunol"},{"key":"498_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jiac.2019.11.011","volume":"27","author":"S Arakawa","year":"2021","unstructured":"Japanese Association for Infectious Diseases\/Japanese Society of Chemotherapy, The JAID\/JSC Guide\/Guidelines to Clinical Management of Infectious Disease Preparing Committee, Sepsis working group, Arakawa S, Kasai M, Kawai S, Sakata H, Mayumi T. The JAID\/JSC guidelines for management of infectious diseases 2017 \u2013 Sepsis and catheter-related bloodstream infection. J Infect Chemother. 2021;27:657\u201377.","journal-title":"J Infect Chemother"},{"key":"498_CR18","first-page":"e01951","volume":"64","author":"M Castanheira","year":"2020","unstructured":"Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Meropenem-Vaborbactam activity against carbapenem-resistant enterobacterales isolates Collected in U.S. hospitals during 2016 to 2018. Antimicrob Agents Chemother. 2020;64:e01951\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"498_CR19","doi-asserted-by":"publisher","first-page":"115964","DOI":"10.1016\/j.bmc.2020.115964","volume":"30","author":"F Ushiyama","year":"2020","unstructured":"Ushiyama F, Takashima H, Matsuda Y, Ogata Y, Sasamoto N, Kurimoto-Tsuruta R, et al. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC Inhibitors: discovery of TP0586532. Bioorg Med Chem. 2020;30:115964 https:\/\/doi.org\/10.1016\/j.bmc.2020.115964.","journal-title":"Bioorg Med Chem"},{"key":"498_CR20","doi-asserted-by":"crossref","unstructured":"Fujita K, Takata I, Yoshida I, Okumura H, Otake K, Takashima H, et al. TP0586532, a Non-Hydroxamate LpxC Inhibitor, has in vitro and in vivo antibacterial activities against Enterobacteriaceae. J Antibiot. (Tokyo). 2021. https:\/\/www.nature.com\/articles\/s41429-021-00486-3. Online ahead of print.","DOI":"10.1038\/s41429-021-00486-3"},{"key":"498_CR21","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard\u2014Tenth Edition. M07\u2013A11. Clinical and Laboratory Standards Institute, Wayne, PA. 2018."},{"key":"498_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1086\/515291","volume":"177","author":"M Norimatsu","year":"1998","unstructured":"Norimatsu M, Morrison DC. Correlation of antibiotic-induced endotoxin release and cytokine production in Escherichia coli-inoculated mouse whole blood ex vivo. J Infect Dis. 1998;177:1302\u20137.","journal-title":"J Infect Dis"},{"key":"498_CR23","unstructured":"GLobal Report On The Epidemiology And Burden Of Sepsis. World Health Organization. 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/334216\/9789240010789-eng.pdf."},{"key":"498_CR24","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46:1552\u201362.","journal-title":"Intensive Care Med"},{"key":"498_CR25","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","volume":"42","author":"R Ferrer","year":"2014","unstructured":"Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749\u201355.","journal-title":"Crit Care Med"},{"key":"498_CR26","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1128\/AAC.39.12.2752","volume":"39","author":"DJ Mason","year":"1995","unstructured":"Mason DJ, Power EG, Talsania H, Phillips I, Gant VA. Antibacterial action of ciprofloxacin. Antimicrob Agents Chemother. 1995;39:2752\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"498_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1099\/00222615-40-1-23","volume":"40","author":"HA Crosby","year":"1994","unstructured":"Crosby HA, Bion JF, Penn CW, Elliott TS. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol. 1994;40:23\u201330.","journal-title":"J Med Microbiol"},{"key":"498_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10156-006-0442-2","volume":"12","author":"S Kawai","year":"2006","unstructured":"Kawai S, Nakagawa T, Sakayori S, Kobayashi O, Kamiya S. Effect of ciprofloxacin on levels of lipopolysaccharide and cytokines in experimentally induced Gram-negative bacterial pneumonia in mice. J Infect Chemother. 2006;12:119\u201323.","journal-title":"J Infect Chemother"},{"key":"498_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijantimicag.2009.11.009","volume":"35","author":"G Wu","year":"2010","unstructured":"Wu G, Fan X, Li L, Wang H, Ding J, Hongbin W, et al. Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli. Int J Antimicrob Agents. 2010;35:250\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"498_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878\u201388.","journal-title":"Biochim Biophys Acta"},{"key":"498_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11498","volume":"7","author":"S Honda","year":"2016","unstructured":"Honda S, Sato K, Totsuka N, Fujiyama S, Fujimoto M, Miyake K, et al. Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion induced by Fc\u03b1\/\u03bcR-coupled TLR4 signalling. Nat Commun. 2016;7:11498.","journal-title":"Nat Commun"},{"key":"498_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10787-019-00628-y","volume":"28","author":"YF Ibrahim","year":"2020","unstructured":"Ibrahim YF, Moussa RA, Bayoumi AMA, Ahmed AI-SF. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-\u03baB\/JNK: a possible role of P-glycoprotein. Inflammopharmacology 2020;28:215\u201330.","journal-title":"Inflammopharmacology"},{"key":"498_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"T Hirano","year":"2020","unstructured":"Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020;52:731\u20133.","journal-title":"Immunity"},{"key":"498_CR34","doi-asserted-by":"publisher","first-page":"165974","DOI":"10.1155\/2013\/165974","volume":"2013","author":"W Schulte","year":"2013","unstructured":"Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets\u2014an updated view. Mediators Inflamm. 2013;2013:165974.","journal-title":"Mediators Inflamm"},{"key":"498_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ags3.12194","volume":"2","author":"S Ono","year":"2018","unstructured":"Ono S, Tsujimoto H, Hiraki S, Aosasa S. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann Gastroenterol Surg. 2018;2:351\u20138.","journal-title":"Ann Gastroenterol Surg"},{"key":"498_CR36","first-page":"669","volume":"27","author":"H Chaudhry","year":"2013","unstructured":"Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013;27:669\u201384.","journal-title":"In Vivo"},{"key":"498_CR37","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1084\/jem.20111354","volume":"208","author":"W Xiao","year":"2011","unstructured":"Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581\u201390.","journal-title":"J Exp Med"},{"key":"498_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2015-1","volume":"10","author":"C Cao","year":"2019","unstructured":"Cao C, Yu M, Chai Y. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death Dis. 2019;10:782.","journal-title":"Cell Death Dis"},{"key":"498_CR39","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4049\/jimmunol.1700375","volume":"199","author":"CW Chen","year":"2017","unstructured":"Chen CW, Mittal R, Klingensmith NJ, Burd EM, Terhorst C, Martin GS, et al. Cutting edge: 2B4-mediated coinhibition of CD4+ T cells underlies mortality in experimental sepsis. J Immunol. 2017;199:1961\u20136.","journal-title":"J Immunol"},{"key":"498_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1301-x","volume":"20","author":"R Shao","year":"2016","unstructured":"Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed death ligand-1 expression after 3\u20134 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20:124.","journal-title":"Crit Care"},{"key":"498_CR41","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms18112413","volume":"18","author":"NK Patil","year":"2017","unstructured":"Patil NK, Guo Y, Luan L, Sherwood ER. Targeting immune cell checkpoints during sepsis. Int J Mol Sci. 2017;18:2413.","journal-title":"Int J Mol Sci"},{"key":"498_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1189\/jlb.0110037","volume":"88","author":"P Brahmamdam","year":"2010","unstructured":"Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233\u201340.","journal-title":"J Leukoc Biol"},{"key":"498_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/SHK.0b013e3182168cce","volume":"36","author":"S Inoue","year":"2011","unstructured":"Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS. Dose dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011;36:38\u201344.","journal-title":"Shock"},{"key":"498_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","volume":"196","author":"VX Liu","year":"2017","unstructured":"Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196:856\u201363.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-021-00498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-021-00498-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-021-00498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:54:54Z","timestamp":1744196094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-021-00498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1038\/s41429-021-00498-z","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}